Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study

Lancet

Volumn 370, Issue 9604, 2007, Pages 2020-2029

  QUASAR Collaborative Group, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

EID: 36849064682     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61866-2     Document Type: Article

References (39)

1. Ferlay J., Bray E., Pisani P., and Parkin D. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase number 5, version 2.0 (2004), IARC Press, Lyon, France
2. Moertel C., Fleming T., Macdonald J., et al. Levamisole and fluorouracil as adjuvant therapy of resected colon carcinoma. N Engl J Med 322 (1990) 352-358
3. Taal B., van Tinteren H., Zoetmulder F., et al. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 85 (2001) 1437-1443
4. Seventh King's Fund Forum. Cancer of the colon and rectum consensus statement. Brit J Surg 77 (1990) 1063-1065
5. Anon. NIH Consensus Conference: adjuvant cancer therapy. JAMA 264 (1990) 1444-1450
6. Francini G., Petrioli R., Lorenzini L., et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 106 (1994) 899-906
7. International Multicentre Pooled Analysis of Colorectal Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345 (1995) 939-944
8. O'Connell M., Mailliard J., Kahn M., et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as post-operative adjuvant therapy for colon cancer. J Clin Oncol 15 (1997) 246-250
9. Wolmark N., Rockette H., Fisher B., et al. The benefit of leucovorin modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11 (1993) 1879-1887
10. Wolmark N., Rockette H., Mamounas E., et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole and fluorouracil, leucovorin, and levamisole in patients with Dukes B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17 (1999) 3553-3559
11. O'Connell M., Laurie J., Kahn M., et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16 (1998) 295-300
12. Haller D., Catalano P., MacDonald J., et al. Phase III study of fluorouracil, leucovorin, and levamisole (LEV) in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23 (2005) 8671-8678
13. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 355 (2000) 1588-1596
14. Kerr D. 5-fluorouracil and folinic acid: interesting biochemistry or effective treatment?. Br J Cancer 60 (1989) 807-808
15. Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22 (2004) 3766-3775
16. Benson A., Schrag D., Somerfield M., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 (2004) 3408-3419
17. Krook J., Moertel C., Gunderson L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324 (1991) 709-715
18. Zittoun J., Marquet J., Pilkorger J., et al. Comparative effect of 6S,6R and 6RS leucovorin on methotrexate rescue and modulation of 5-fluorouracil. Br J Cancer 63 (1991) 885-888
19. Kerr D., Gray R., McConkey C., et al. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules-less pain, same gain. Ann Oncol 11 (2000) 947-955
20. Collins R., Peto R., Gray R., and Parish S. Large-scale randomized evidence: trials and overviews. In: Weatherall D., Ledingham J., and Warrell D. (Eds). Oxford textbook of medicine volume 1 (1996), Oxford University Press, Oxford, UK 21-32
21. Aaronson N., Ahmedzai S., Bergman B., et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
22. Davidson-Homewood J., Norman A., Küchler T., Cunningham D., and Watson M. Development of a disease specific questionnaire to supplement a generic tool for QoL in colorectal cancer. Psychooncology 12 (2003) 675-685
23. Zigmond A., and Snaith R. The hospital anxiety and depression scale. Acta Psychiatr Scand 67 (1983) 361-370
24. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer, volume 1, worldwide evidence 1985-1990 (1990), Oxford University Press, Oxford, UK. http://www.ctsu.ox.ac.uk/reports/ebctg-1990.html (accessed Dec 3, 2007).
25. Sargent D., Wieand H., Haller D., et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23 (2005) 8664-8670
26. Melville A., Sheldon T., Gray R., and Sowden A. Management of colorectal cancer. Qual Health Care 7 (1998) 103-108
27. Mamounas C., Wieand S., Wolmark N., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four national surgical adjuvant breast and bowel project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17 (1999) 1349-1355
28. Gill S., Loprinzi C., Sargent D., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: what benefits and by how much?. J Clin Oncol 22 (2004) 1797-1806
29. Glimelius B., Dahl O., Cedermark B., et al. Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncologica 44 (2005) 904-912
30. Figueredo A., Charette M., Maroun J., Brouwers M., and Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care on Ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22 (2004) 3395-3407
31. Smith R., Colangelo L., Wieand H., Begovic M., and Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP Protocol C-01. J Natl Cancer Inst 96 (2004) 1128-1132
32. Sargent D., Goldberg R., Jacobson S., et al. A pooled analysis of adjuvant chemotherapy for resected colorectal cancer in elderly patients. N Engl J Med 345 (2001) 1091-1097
33. Goldberg R., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24 (2006) 4085-4091
34. Jansen S., Otten W., and Stiggelbout A. Review of determinants of patients' preferences for adjuvant therapy in cancer. J Clin Oncol 22 (2004) 3181-3190
35. Twelves C., Wong A., Nowacki M., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 (2005) 2696-2704
36. André T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
37. Wolmark N., Wieand H., Kuebler L., et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or II carcinoma of the colon: results of NSABP protocol C-07. Proc Am Soc Clin Oncol 23 (2005) 16S
38. Schmoll H., Cartwright T., Tabernero J., et al. Phase II trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25 (2007) 102-109
39. Smith R., Colangelo L., Wieand H., et al. The occurrence of severe enteropathy among patients with stage II/III resected colon cancer (CC) treated with 5-FU/leucovorin (FL) plus oxaliplatin (FLOX). Proc Am Soc Clin Oncol 22 (2003) 294